Kailera Therapeutics Inc.
Organization details
- Legal name
- Kailera Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KLRA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002096997
Board of directors
-
Adam Koppel · DirectorSince 2026
-
Andrew T. Kaplan · DirectorSince 2026
-
Christopher Hite · DirectorSince 2026
-
Frank Clyburn · DirectorSince 2026
-
John F. Milligan · DirectorSince 2026
-
Martin Mackay · DirectorSince 2026
-
Ronald C. Renaud Jr. · Director · CEO & PresidentSince 2026
-
Yuting Liu · DirectorSince 2026
Chief executives
Board connections
7 of this board's directors also sit on 11 other boards. 10 are in the same sector.
-
4D Molecular Therapeutics Inc. Same sectorvia John F. Milligan
-
Cencora Inc. Same sectorvia Frank Clyburn
-
Charles River Laboratories International Inc. Same sectorvia Martin Mackay
-
Foghorn Therapeutics Inc. Same sectorvia Adam Koppel
- via John F. Milligan
-
Rallybio Corporation Same sectorvia Martin Mackay
-
Revolution Medicines Inc. Same sectorvia Frank Clyburn
-
Solid Biosciences Inc. Same sectorvia Adam Koppel
-
Surgery Partners Inc. Same sectorvia Andrew T. Kaplan
-
Upstream Bio Inc. Same sectorvia Ronald C. Renaud Jr.
-
Vera Therapeutics Inc. Same sectorvia Christopher Hite
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $326,750,016
- 5 purchases by 5 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 9, 2026 | Ronald C. Renaud Jr. Director, Officer (CEO & President) | Option exercise | +38,094 | $5.25 | $199,994 |
| Apr 20, 2026 | RTW INVESTMENTS, LP 10% owner | Derivative conversion | +10,276,820 | — | — |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Derivative conversion | +9,477,719 | — | — |
| Apr 20, 2026 | BCPE Perseus Investor, LP 10% owner | Derivative conversion | +17,857,143 | — | — |
| Apr 20, 2026 | Adam Koppel Director, 10% owner | Derivative conversion | +16,875,000 | — | — |
| Apr 20, 2026 | BCLS Fund IV Investments GP, LLC 10% owner | Derivative conversion | +16,875,000 | — | — |
| Apr 20, 2026 | Andrew T. Kaplan Director, 10% owner | Derivative conversion | +17,857,143 | — | — |
| Apr 20, 2026 | RTW INVESTMENTS, LP 10% owner | Open-market purchase | +500,000 | $16.00 | $8,000,000 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Derivative conversion | +2,034,133 | — | — |
| Apr 20, 2026 | BCPE Perseus Investor, LP 10% owner | Open-market purchase | +8,398,438 | $16.00 | $134,375,008 |
| Apr 20, 2026 | Adam Koppel Director, 10% owner | Derivative conversion | +4,145,768 | — | — |
| Apr 20, 2026 | BCLS Fund IV Investments GP, LLC 10% owner | Derivative conversion | +4,145,768 | — | — |
| Apr 20, 2026 | Andrew T. Kaplan Director, 10% owner | Open-market purchase | +8,398,438 | $16.00 | $134,375,008 |
| Apr 20, 2026 | Adam Koppel Director, 10% owner | Open-market purchase | +1,562,500 | $16.00 | $25,000,000 |
| Apr 20, 2026 | BCLS Fund IV Investments GP, LLC 10% owner | Open-market purchase | +1,562,500 | $16.00 | $25,000,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Kailera Therapeutics Inc.
Who is the CEO of Kailera Therapeutics Inc.?
Ronald C. Renaud Jr. has been Kailera Therapeutics Inc.'s CEO & President since April 2026.
How many directors are on Kailera Therapeutics Inc.'s board?
Kailera Therapeutics Inc.'s board has 8 directors: Adam Koppel, Andrew T. Kaplan, Christopher Hite, Frank Clyburn, John F. Milligan, Martin Mackay, Ronald C. Renaud Jr. and Yuting Liu.
Are Kailera Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Kailera Therapeutics Inc. insiders bought $326.8 million of shares in 5 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="kailera-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.